Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.

@article{Dougados2001EfficacyOC,
  title={Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.},
  author={Maxime R Dougados and Jehan Michel Behier and I Jolchine and Andrei Calin and D{\'e}sir{\'e}e Mfm van der Heijde and Ignazio Olivieri and Henning K Zeidler and Hermawan Herman},
  journal={Arthritis and rheumatism},
  year={2001},
  volume={44 1},
  pages={180-5}
}
OBJECTIVE To evaluate the short-term efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis (AS). METHODS The study was a 6-week randomized, double-blind, placebo-controlled trial with 3 treatment arms: placebo, ketoprofen 100 mg twice daily, and celecoxib 100 mg twice daily. Patients who had AS according to the modified New York criteria, without peripheral synovitis and with active disease (pain > or =40 mm on a 100-mm visual analog scale… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 62 extracted citations

Celecoxib for the Treatment of Ankylosing Spondylitis

Jian Zhu, Cindi Sounthonevat, Chris Walker
2017
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…